AbbVie's Q3 2025 earnings are in. Skyrizi is on fire, neuroscience is booming, but Botox is a bust. Get the summary.

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

In an increasingly crowded psoriasis market, a raft of next-gen biologics is looking to topple an older suite of drugs for sales supremacy. Dermatologists seem to be on board with that shift, a good ...

Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.

AbbVie Inc. ABBV announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved its key pipeline candidate, risankizumab, for the treatment of adult patients with plaque ...

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...

AbbVie leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira, an analyst said Friday as ...

Researchers from King’s College London (KCL) have investigated the early effects of AbbVie’s immunosuppressant drug, Skyrizi (risankizumab), which could help clinicians develop personalised treatment ...

AbbVie (NYSE:ABBV) announced Wednesday that its FDA-approved immunology therapy, Skyrizi, outperformed Amgen’s (NASDAQ:AMGN) blockbuster therapy, Otezla, in a Phase 4 head-to-head study for adults ...

AbbVie Inc ABBV announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi (risankizumab) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Skyrizi is now available as a single-dose 150 mg ...

AbbVie (ABBV-0.69%) and Boehringer Ingelheim's Skyrizi performed better than Novartis' (NVS-0.32%) Cosentyx in a head-to-head late stage clinical trial in patients with the plaque psoriasis, an ...